STOCK TITAN

Amedisys Inc Stock Price, News & Analysis

AMED Nasdaq

Welcome to our dedicated page for Amedisys news (Ticker: AMED), a resource for investors and traders seeking the latest updates and insights on Amedisys stock.

Amedisys Inc (NASDAQ: AMED) provides essential home healthcare, hospice, and high-acuity care services across the United States. This news hub offers investors and industry professionals direct access to verified corporate announcements and financial updates from the home healthcare leader.

Track material developments including quarterly earnings reports, regulatory filings, clinical program expansions, and strategic partnerships. Our curated collection features official press releases, SEC disclosures, and market-moving updates - all organized chronologically for efficient research.

Key content categories include financial performance updates, Medicare/Medicaid compliance changes, care center acquisitions, leadership appointments, and clinical quality initiatives. Bookmark this page for real-time access to operational milestones that shape AMED's position in the $300B home healthcare market.

For stakeholders monitoring the shift toward value-based care models, this resource simplifies tracking of Amedisys' evolving service offerings and regulatory compliance status. Visit regularly to stay informed about critical developments affecting one of America's largest home health providers.

Rhea-AI Summary

Amedisys, Inc. (NASDAQ: AMED) reported Q2 2020 net service revenue of $485 million, down $8 million from $493 million in 2019. Net income increased to $34.7 million ($1.04 per diluted share) from $33.7 million ($1.02) year-over-year. Year-to-date revenue rose to $976.7 million, with net income of $66.5 million ($2.00 per diluted share), up from $65 million ($1.98). The company reaffirmed its 2020 guidance, anticipating annual net revenue between $2.040 billion and $2.070 billion and adjusted EBITDA of $245 million to $255 million. CEO Paul B. Kusserow highlighted company resilience during the COVID-19 pandemic.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.53%
Tags
-
Rhea-AI Summary

Amedisys, Inc. (NASDAQ: AMED) will report its Q2 results for the period ending June 30, 2020, after market close on July 28, 2020. An investor conference call will be held the next day, July 29, 2020, at 11:00 a.m. ET to discuss these results. Participants can join via telephone or listen to a live webcast on the company’s Investor Relations page. Amedisys is a leader in healthcare at home, offering personalized home health, hospice, and personal care to over 415,000 patients annually, with a workforce of 21,000 across 526 care centers in 39 states.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.16%
Tags
-
Rhea-AI Summary

Amedisys, Inc. (NASDAQ: AMED) announced that its President and CEO, Paul B. Kusserow, will present at the 2020 BMO Prescriptions for Success Healthcare Conference on June 23, 2020, at 1:00 p.m. Eastern Time. Amedisys, a leading home health, hospice, and personal care company, emphasizes personalized care and has partnerships with over 2,600 hospitals and 67,000 physicians. The company serves more than 415,000 patients annually across 39 states and the District of Columbia, employing 22,000 staff in 524 care centers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.39%
Tags
conferences
Rhea-AI Summary

Amedisys, a leading home health and hospice company, announced that CEO Paul B. Kusserow will present at the 40th Annual William Blair Growth Stock Conference on June 10, 2020, at 3:00 p.m. Eastern Time. Investors can access the live webcast on the company’s website. Amedisys operates across 39 states, providing personalized care to over 415,000 patients annually. With 22,000 employees and 524 care centers, the company partners with over 2,600 hospitals and 67,000 physicians nationwide, focusing on delivering high-quality home-based healthcare.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.2%
Tags
conferences
-
Rhea-AI Summary

Amedisys (NASDAQ: AMED) has completed its acquisition of AseraCare Hospice for $235 million, with a net purchase price of $203 million after accounting for a $32 million tax asset. This acquisition expands Amedisys' hospice services, increasing their care centers to 190 across 35 states and serving approximately 14,000 patients daily. AseraCare, with annual revenues of around $117 million, has 44 locations and employs over 1,200 hospice professionals. Amedisys aims to enhance patient care and reach more communities with this strategic move.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.51%
Tags
-
Rhea-AI Summary

Amedisys, a leading home health and hospice provider, announced that CEO Paul B. Kusserow will present at the 2020 Jefferies Virtual Healthcare Conference on June 2, 2020, at 11:00 a.m. Eastern Time. The presentation can be accessed via a live webcast on Amedisys' investor relations website. Founded in 1982, Amedisys focuses on delivering personalized care to patients across 38 states and the District of Columbia, partnering with over 2,600 hospitals and 67,000 physicians nationwide to provide high-quality home-based care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.59%
Tags
conferences
Rhea-AI Summary

Amedisys, Inc. (NASDAQ: AMED) announced that CEO Paul B. Kusserow will present at the RBC Capital Markets 2020 Global Healthcare Conference on May 19, 2020, at 1:20 p.m. ET. Investors can access the live webcast through Amedisys’ website.

Founded in 1982 and headquartered in Baton Rouge, LA, Amedisys is a leading provider of home health, hospice, and personal care services, serving over 415,000 patients annually with a workforce of more than 21,000 employees across 480 care centers in 38 states and the District of Columbia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences
-
Rhea-AI Summary

Amedisys, Inc. (NASDAQ: AMED) will be presenting at the UBS Global Healthcare Conference 2020 on May 18, 2020, at 3:00 p.m. Eastern Time. Paul B. Kusserow, the President and CEO, will lead the presentation. Investors can access the live webcast on the Amedisys investor relations website. Amedisys is recognized for its home health, hospice, and personal care services, ensuring quality care for over 415,000 patients annually. The company operates 480 care centers across 38 states and the District of Columbia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.83%
Tags
conferences
-
Rhea-AI Summary

Amedisys, Inc. (NASDAQ: AMED) reported a net service revenue of $491.7 million for Q1 2020, an increase of $24.4 million from 2019. Net income rose to $31.8 million, with earnings per share at $0.96. However, adjusted EBITDA decreased to $53.3 million from $54.9 million in 2019. Due to the ongoing COVID-19 pandemic, the company has withdrawn its full-year guidance, citing uncertainty in its financial outlook. Amedisys emphasizes the resilience of its business model and commitment to quality care.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.89%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.18%
Tags
none

FAQ

What is the current stock price of Amedisys (AMED)?

The current stock price of Amedisys (AMED) is $98.03 as of June 26, 2025.

What is the market cap of Amedisys (AMED)?

The market cap of Amedisys (AMED) is approximately 3.2B.
Amedisys Inc

Nasdaq:AMED

AMED Rankings

AMED Stock Data

3.20B
32.18M
2.09%
91.58%
8.81%
Medical Care Facilities
Services-home Health Care Services
Link
United States
BATON ROUGE